Coronary Artery Disease Without Heart Failure Clinical Trial
— CORANAEOfficial title:
Short and Fast Step Test: Feasibility, Validity and Tolerance of a Functional Evaluation Test of Lactic Anaerobic Capacities in Patients With Coronary Artery Disease
Verified date | September 2019 |
Source | Centre Hospitalier Universitaire Dijon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Recommendations for cardiovascular rehabilitation (CVR) encourage exercise training, primarily involving the aerobic system, to allow patients to regain independence in daily activities. However, the lactic anaerobic process is also involved during these activities (stair climbing, carrying loads, etc.). Hence there is a major interest in accurately assessing patients' anaerobic capacities in order to tailor suitable exercise programs. However, there are no functional tests specifically dedicated to the evaluation of lactic anaerobic metabolism and adapted to people with coronary disease. The investigators offer a dedicated test, the short and fast test (SFST), which can be applied in current clinical practice and has already been evaluated in a population of healthy subjects. The purpose of this project is to evaluate the safety, feasibility and validity of SFST in a population of patients with coronary artery disease.
Status | Completed |
Enrollment | 44 |
Est. completion date | May 3, 2019 |
Est. primary completion date | May 3, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient who has given oral consent Adult patient (male or female) with coronary artery disease without heart failure referred for rehabilitation program Left ventricular ejection fraction (Simpson method) > 45%. Exclusion Criteria: - Protected adult - Patient not affiliated to a national health insurance scheme - Pregnant or breastfeeding woman - Orthostatic hypotension - Severe obstructive heart disease - aortic valve narrowing - Progressive severe cardiac rhythm or conduction disorders not requiring a device, detected during the initial stress test. - intracavitary cardiac thrombus - severe pulmonary arterial hypertension (systolic pulmonary hypertension >70mmHg) - recent venous thromboembolic history (last 3 months) - heart transplantation - associated medical condition that can predominantly impair functional and respiratory capacities (examples: unstabilized metabolic disorders such as progressive renal failure, significant asthenia related to a severe unstabilized condition such as neoplasia, systemic disease, chronic obstructive pulmonary disease...) - physical impairments of the lower limbs hindering the test, whether neurological (central or peripheral), arterial (in particular, arteriopathy of the lower limbs with systolic index < 0.6) or orthopedic (degenerative or inflammatory rheumatism) - Treatment with Corticosteroids, Anabolics, or L-Carnitine. |
Country | Name | City | State |
---|---|---|---|
France | CHU de DIJON | Dijon |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire Dijon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | percentage of patients who completed the SFST without complications | - Absence of muscular or bone-joint disorders quantified according to the VAS. The exercise will be considered as not tolerated if pain is reported during the test and/or at day 3 (VAS=6). AND no falls or stumbling related trauma AND absence of cardiovascular or blood pressure events: Hypertension (systolic pressure greater than 250 mmHg (O'Brien et al. 2005) or hypotension with clinical consequences (malaise or feeling unwell) Discomfort, chest pain, onset of vascular claudication Rhythm or conduction disorders or repolarization abnormalities, at a higher frequency than that observed in the pre-inclusion stress test Abnormal increase in heart rate (greater than the maximum rate determined during the stress test). |
through study completion, an average of 11 days |